All In Biotech

Drug Trial Radar · NCT07745907

A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 691 Administered in Healthy Chinese and Japanese Participants

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Aug 7, 2026

Primary completion

Mar 17, 2027

Study completion Mar 17, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants

Conditions

  • Healthy Participants

Interventions

  • AMG 691Drug

    AMG 691 will be administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Serum Concentration (Cmax) of AMG 691Time frame: Day 1 up to Day 154
  2. Area Under the Serum Concentration Time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of AMG 691Time frame: Up to Day 154
  3. Area Under the Serum concentration Time Curve from Time Zero to Infinity (AUC0-inf) of AMG 691Time frame: Up to Day 154

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD - Las Vegas Research Unit

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.